SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
294 40 0 TRIL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
94ASH abstracts now available, and TRIL has 2. 1/6 OR in DLBCL for monotherapy, btuck-11/1/2017
93Good size round B, Forty Seven Inc...... markets.businessinsider.com (pointer scaram(o)uche-10/17/2017
92TRIL analysis from "Seeking Alpha" seekingalpha.com Summary Shares hBladerunner17-10/15/2017
91Competition . . . "tril-investor" handicaps the players ituck-10/5/2017
90Getting ready for clear above 5.35. [graphic]hollyhunter-10/3/2017
89Here is the link its 1:30pm (Eastern) wsw.com BTW for those that don't knowghmm19/28/2017
88Tuck, I talked to Jim Parsons today. TRIL will have a poster at ASH. On TRIL&Bladerunner17-9/27/2017
87>>>> asked by the company to change its business description in the tuck18/31/2017
86So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET ituck-8/31/2017
85I wonder about the CD200 program. There doesn't seem to be the same level oftuck-8/4/2017
84So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET ituck-7/5/2017
83That occurred to me, and may be a part of it. So far, the in vivo experiments htuck-6/26/2017
82>>>Then inexplicably off 10% today to new lows. Could be end-of-quarteBulbaMan-6/26/2017
81PD-1 combo now being studied. With Nivolumab, as an expansion of the ongoing P1tuck-6/26/2017
80Updating the Novimmune bispecific effort. In addition to the CD47/CD19 bispeciftuck-4/4/2017
79Can't find the post, but somewhere around here I said that it was possible tscaram(o)uche-3/31/2017
78Here is another anti-CD47/PD-1 combo study, this time in a model of esophogeal ctuck-3/27/2017
77Thanks for pointing, I did not saw early. Seams that priority date was 2008!Miljenko Zuanic-3/6/2017
76Lead finding technology is in the lead finding stage..... synthon.com Shockingscaram(o)uche-3/5/2017
75The sanquin stuff looks, first blush, like it was written to exclude anything rescaram(o)uche-3/5/2017
74Timely find, too: Synthon just licensed it. Synthon enters worldwide exclusive tuck-3/3/2017
73When cancer is drug target, I am not much concerned about legal IP right and figMiljenko Zuanic-3/2/2017
72Good find, Miljenko. Not sure how this squares against TRIL's IP. Van den tuck-3/2/2017
71One of the competitor: sanquin.nlMiljenko Zuanic-3/2/2017
70Thanks Tuck. Judging by TRIL’s less than enthusiastic stock response to the PR aBulbaMan-2/24/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News